Make Better Decisions With DrugPatentWatch
MAKE BETTER DECISIONS Join the 500+ leading biopharmaceutical companies we have served and make better decisions with DrugPatentWatch’s deep knowledge […]
MAKE BETTER DECISIONS Join the 500+ leading biopharmaceutical companies we have served and make better decisions with DrugPatentWatch’s deep knowledge […]
Although currently tiny and narrowly focused on a handful of disease areas and countries, the biosimilar industry is set to
For the last century, drug development consisted of tiny-molecule treatments focused at mass audience. It worked for some patients while
This article was originally published by Christopher Southan, Peter Varkonyi, Kiran Boppana, Sarma A.R.P. Jagarlapudi, and Sorel Muresan at PLoS ONE
Tracking 20 Years of Compound-to-Target Output from Literature and Patents Read Post »
By Larry Ramer, DrugPatentWatch writer Artificial intelligence, or AI, has advanced significantly in recent years and could significantly lower pharma
Can Artificial Intelligence Help Drug Development? Read Post »
By: Pankaj Mondal, DrugPatentWatch Staff Writer When it comes to measuring the success of a new drug, the amount of
By: Pankaj Mondal, DrugPatentWatch Staff Writer The US pharmaceutical industry is heavily competitive, with nine out of the top ten
The Importance of Pharmaceutical Competitor Analysis Read Post »
This article was originally published on November 30th 2017 by Hamish McDougall and Alaric DeArment of BioPharm Insight, part of
Consumer access to effective and affordable medicines is an imperative for public health, social equity, and economic development, but this
Making Medicines Affordable: A National Imperative Read Post »